Ranbaxy Laboratories Limited - Strategy and SWOT Report

Jan 23, 2015 - MarketLine - 52 pages - USD $175
Abstract Table of Contents Companies Request Details Related
Ranbaxy Laboratories Limited - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360deg view of the company.

Report Features
  • Detailed information on Ranbaxy Laboratories Limited required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Ranbaxy Laboratories Limited in the form of a SWOT analysis
  • An in-depth view of the business model of Ranbaxy Laboratories Limited including a breakdown and examination of key business segments
  • Intelligence on Ranbaxy Laboratories Limited's mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
  • News about Ranbaxy Laboratories Limited, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends
Report Highlights

Ranbaxy Laboratories Limited (Ranbaxy or 'the company'), a subsidiary of Daiichi Sankyo, is a leading generic pharmaceutical company in India. It is engaged in the production, distribution and marketing of generics, value-added and over-the-counter (OTC) products, anti-retroviral (ARV), active pharmaceuticals ingredients (API), and intermediates. The company operates in Asia Pacific, Americas, Europe, Middle East and Africa. It is headquartered in Gurgaon, India, and employed 11,784 people as of March 31, 2014. The company recorded revenues of INR132,684.8 million (approximately $2,255.6 million) during the 15-month period ended March 31, 2014. The operating profit of the company was INR6,851.5 million (approximately $116.4 million) and the net loss was INR10,852.5 million (approximately $184.5 million) during the 15-month period. Ranbaxy changed its financial year from January-December to April-March, and reported financial for the 15-month period ended March 31, 2014. Hence, the company's financials for the 15-month period cannot be compared with the financials of FY2012. In April 2014, Ranbaxy and Sun Pharmaceutical Industries (Sun Pharma), an India-based leading generic manufacturer, entered into definitive agreements pursuant to which Sun Pharma will acquire 100% of Ranbaxy in an all-stock transaction.

Reasons to Get this Report
  • Gain understanding of Ranbaxy Laboratories Limited and the factors that influence its strategies
  • Track strategic initiatives of the company and latest corporate news and actions
  • Assess Ranbaxy Laboratories Limited as a prospective partner, vendor or supplier
  • Support sales activities by understanding your customers' businesses better
  • Stay up to date on Ranbaxy Laboratories Limited's business structure, strategy and prospects

Order This Report
LICENSE: Single-User
DELIVERY: Instant Download

Once you’ve found the right report, click ‘order now’ and complete the checkout process using any major credit card, check or wire/bank transfer.

Need multi-user or enterprise license pricing? Contact us for a custom quote!
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away

About the Publisher
MarketLine is a global publisher of company, industry and country information. Their clients operate across a wide variety of industries and job functions and range from multinational corporations right down to small businesses in both developed and developing economies. MarketLine users enjoy access to content that is trustworthy, up to date and reasonably priced and routinely turn to them as their first-stop resource for instantly accessible, reliable business information. MarketLine is wholly owned subsidiary of Datamonitor.